Home > Press Releases > AI in Pharmacovigilance Market

AI in Pharmacovigilance Market Likely to Surpass USD 1.9 Billion by 2035

Report Code: HC-88255  |  Published in: Jul 2026, By MarketGenics  |  Number of pages: 298
Get PDF
Buy

Global AI in Pharmacovigilance Market Forecast 2035:

According to the report, the global AI in pharmacovigilance market is projected to expand from USD 0.4 billion in 2025 to USD 1.9 billion by 2035, registering a CAGR of 17.1%, the highest during the forecast period. The AI in pharmacovigilance segment is growing as the volume of adverse events continues to rise, regulatory agencies are placing increased importance on speedy adverse event reporting, cloud-based pharmacovigilance platforms are gaining acceptance, and generative AI is increasingly being used to automate case processing, literature review, and signal detection.

Real-world evidence and analytics from electronic health records are also being incorporated in the development of predictive drug safety monitoring and regulatory compliance by drug companies. For instance, in November 2025, HiroPharmaConsulting has won the first Japanese patent for pharmacovigilance validation using AI, introducing a regulatory compliant framework for reliable, auditable, and continuously validated AI pharmacovigilance systems.

Further, the U.S. Food and Drug Administration (FDA) is still making strides in promoting the responsible use of AI in drug development and pharmacovigilance by providing guidance in a risk-based manner to facilitate greater adoption of AI to support drug safety technologies. This is driving the smart, conformant and predictive pharmacovigilance ecosystem and continues to fuel growth in the market.                  

Key Driver, Restraint, and Growth Opportunity Shaping the Global AI in Pharmacovigilance Market

The growing use of multilingual AI and natural language processing is enabling pharmaceutical companies to process adverse event reports from diverse languages, scientific literature, social media, and regional regulatory databases with greater speed and consistency. This facilitates global safety surveillance, decrease in translation delays, data standardization, and facilitates quicker submission to regulatory authorities in various international markets.                                      

The limited availability of professionals with expertise in both artificial intelligence and pharmacovigilance is constraining AI adoption. Organizations face challenges in AI model validation, safety data interpretation, governance, and regulatory compliance, increasing implementation complexity, operational costs, and deployment timelines.                    

The expansion of the AI use in pharmacovigilance is being driven by the rising use of wearable devices, mHealth apps, patient support initiatives and digital therapeutics. Patient-generated health data can be continuously analyzed by AI to detect new safety concerns earlier, to facilitate real-world safety monitoring and to guide personalized benefit-risk assessments throughout product lifecycle.          

Expansion of the Global AI in Pharmacovigilance Market

Expansion of Predictive Pharmacovigilance Using Machine Learning Analytics

  • The growth of predictive pharmacovigilance, powered by machine learning analytics is trend that is prompting pharmaceutical companies to embrace AI to anticipate and detect potential safety hazards before they arise as serious adverse events. Machine learning models can identify patterns, risk signals, and enhance signal detection by processing vast amounts of clinical, real-world, and post-marketing safety information.
  • This predictive approach enables proactive risk management, speeds up regulatory decision making, decreases manual analysis and increases overall patient safety while improving the efficiency of all pharmacovigilance functions.
  • Predictive AI analytics are helping to identify safety signals earlier in the drug lifecycle, enhancing risk mitigation and driving proactive pharmacovigilance.                          

Regional Analysis of Global AI in Pharmacovigilance Market

  • North America accounts for the highest demand in the AI in pharmacovigilance market owing to the well-established pharmaceutical industry, advanced healthcare information technology infrastructure and widespread use of AI-based pharmacovigilance solutions across the region. Pharma companies and contract research organizations are rapidly adopting intelligent pharmacovigilance solutions as a result of heavy investments in cloud computing, real-world evidence analytics, and digital health technologies, along with strict regulatory mandates. The digital ecosystem in North America is further strengthening its position as a leader in pharmacovigilance and regulatory innovation with advanced AI capabilities.
  • Asia Pacific is experiencing the fastest growth owing to the rapid growth of the pharmaceutical manufacturing, clinical trials and pharmacovigilance outsourcing market in China, India, Japan and South Korea. AI, healthcare digitalization, and safety platforms that operate on the cloud are driving technology adoption. Across pharmaceutical companies and CROs, AI-powered pharmacovigilance adoption is gaining momentum due to government support for digital healthcare, increased investments in life sciences, and changing regulatory landscape.      

Prominent players operating in the global AI in pharmacovigilance market is Cognizant Technology Solutions, Accenture, ArisGlobal, Capgemini SE, ICON plc, IQVIA, Oracle Corporation, Parexel International Corporation, Tata Consultancy Services (TCS), Wipro Limited, Other Key Players.      

The global AI in pharmacovigilance market has been segmented as follows:

Global AI in Pharmacovigilance Market Analysis, By Component

  • Software
    • Standalone Software
    • Integrated/Embedded Software
  • Services
    • Professional Services
      • Consulting
      • Implementation & Integration
      • Training & Education
    • Managed Services  

Global AI in Pharmacovigilance Market Analysis, By Technology

  • Machine Learning
  • Natural Language Processing (NLP)
  • Deep Learning
  • Robotic Process Automation (RPA)
  • Computer Vision
  • Predictive Analytics
  • Others

Global AI in Pharmacovigilance Market Analysis, By Deployment Mode

Global AI in Pharmacovigilance Market Analysis, By Process Stage

  • Case Intake & Triage
  • Case Data Entry & Processing
  • Medical Review & Assessment
  • Signal Detection & Validation
  • Regulatory Submission & Reporting
  • Quality Control & Audit

Global AI in Pharmacovigilance Market Analysis, By Application

  • Adverse Event Detection and Reporting
  • Case Processing and Triage
  • Signal Detection and Management
  • Literature Monitoring & Screening
  • Regulatory Reporting & Submission
  • Medical Coding
  • Data Mining and Analytics
  • Risk Management & Benefit-Risk Assessment
  • Social Media & Real-World Data Monitoring
  • Other Applications

Global AI in Pharmacovigilance Market Analysis, By End-users

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Medical Device Companies
  • Regulatory Authorities
  • Academic and Research Institutes
  • Others

Global AI in Pharmacovigilance Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global AI in Pharmacovigilance Market Outlook
      • 2.1.1. AI in Pharmacovigilance Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2026-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. AI adoption for automated adverse event detection and signal management
        • 4.1.1.2. Rising real-world data volume driving advanced pharmacovigilance analytics
        • 4.1.1.3. Regulatory focus on faster drug safety monitoring and compliance
      • 4.1.2. Restraints
        • 4.1.2.1. Data privacy and regulatory compliance challenges
        • 4.1.2.2. Limited standardized datasets reducing AI model accuracy
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Ecosystem Analysis         
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global AI in Pharmacovigilance Market Demand
      • 4.7.1. Historical Market Size – in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size – in Value (US$ Bn), 2026–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global AI in Pharmacovigilance Market Analysis, by Component
    • 6.1. Key Segment Analysis
    • 6.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
      • 6.2.1. Software
        • 6.2.1.1. Standalone Software
        • 6.2.1.2. Integrated/Embedded Software
      • 6.2.2. Services
        • 6.2.2.1. Professional Services
          • 6.2.2.1.1. Consulting
          • 6.2.2.1.2. Implementation & Integration
          • 6.2.2.1.3. Training & Education
        • 6.2.2.2. Managed Services
  • 7. Global AI in Pharmacovigilance Market Analysis, by Technology
    • 7.1. Key Segment Analysis
    • 7.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
      • 7.2.1. Machine Learning
      • 7.2.2. Natural Language Processing (NLP)
      • 7.2.3. Deep Learning
      • 7.2.4. Robotic Process Automation (RPA)
      • 7.2.5. Computer Vision
      • 7.2.6. Predictive Analytics
      • 7.2.7. Others
  • 8. Global AI in Pharmacovigilance Market Analysis, by Deployment Mode
    • 8.1. Key Segment Analysis
    • 8.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
      • 8.2.1. Cloud-Based
      • 8.2.2. On-Premise
      • 8.2.3. Hybrid
  • 9. Global AI in Pharmacovigilance Market Analysis, by Process Stage
    • 9.1. Key Segment Analysis
    • 9.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Process Stage, 2021-2035
      • 9.2.1. Case Intake & Triage
      • 9.2.2. Case Data Entry & Processing
      • 9.2.3. Medical Review & Assessment
      • 9.2.4. Signal Detection & Validation
      • 9.2.5. Regulatory Submission & Reporting
      • 9.2.6. Quality Control & Audit
  • 10. Global AI in Pharmacovigilance Market Analysis, by Application
    • 10.1. Key Segment Analysis
    • 10.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
      • 10.2.1. Adverse Event Detection and Reporting
      • 10.2.2. Case Processing and Triage
      • 10.2.3. Signal Detection and Management
      • 10.2.4. Literature Monitoring & Screening
      • 10.2.5. Regulatory Reporting & Submission
      • 10.2.6. Medical Coding
      • 10.2.7. Data Mining and Analytics
      • 10.2.8. Risk Management & Benefit-Risk Assessment
      • 10.2.9. Social Media & Real-World Data Monitoring
      • 10.2.10. Other Applications
  • 11. Global AI in Pharmacovigilance Market Analysis, by End-users
    • 11.1. Key Segment Analysis
    • 11.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by End-users, 2021-2035
      • 11.2.1. Pharmaceutical Companies
      • 11.2.2. Biotechnology Companies
      • 11.2.3. Contract Research Organizations (CROs)
      • 11.2.4. Medical Device Companies
      • 11.2.5. Regulatory Authorities
      • 11.2.6. Academic and Research Institutes
      • 11.2.7. Others
  • 12. Global AI in Pharmacovigilance Market Analysis, by Region
    • 12.1. Key Findings
    • 12.2. AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
      • 12.2.1. North America
      • 12.2.2. Europe
      • 12.2.3. Asia Pacific
      • 12.2.4. Middle East
      • 12.2.5. Africa
      • 12.2.6. South America
  • 13. North America AI in Pharmacovigilance Market Analysis
    • 13.1. Key Segment Analysis
    • 13.2. Regional Snapshot
    • 13.3. North America AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 13.3.1. Component
      • 13.3.2. Technology
      • 13.3.3. Deployment Mode
      • 13.3.4. Process Stage
      • 13.3.5. Application
      • 13.3.6. End-users
      • 13.3.7. Country
        • 13.3.7.1. USA
        • 13.3.7.2. Canada
        • 13.3.7.3. Mexico
    • 13.4. USA AI in Pharmacovigilance Market
      • 13.4.1. Country Segmental Analysis
      • 13.4.2. Component
      • 13.4.3. Technology
      • 13.4.4. Deployment Mode
      • 13.4.5. Process Stage
      • 13.4.6. Application
      • 13.4.7. End-users
    • 13.5. Canada AI in Pharmacovigilance Market
      • 13.5.1. Country Segmental Analysis
      • 13.5.2. Component
      • 13.5.3. Technology
      • 13.5.4. Deployment Mode
      • 13.5.5. Process Stage
      • 13.5.6. Application
      • 13.5.7. End-users
    • 13.6. Mexico AI in Pharmacovigilance Market
      • 13.6.1. Country Segmental Analysis
      • 13.6.2. Component
      • 13.6.3. Technology
      • 13.6.4. Deployment Mode
      • 13.6.5. Process Stage
      • 13.6.6. Application
      • 13.6.7. End-users
  • 14. Europe AI in Pharmacovigilance Market Analysis
    • 14.1. Key Segment Analysis
    • 14.2. Regional Snapshot
    • 14.3. Europe AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 14.3.1. Component
      • 14.3.2. Technology
      • 14.3.3. Deployment Mode
      • 14.3.4. Process Stage
      • 14.3.5. Application
      • 14.3.6. End-users
      • 14.3.7. Country
        • 14.3.7.1. Germany
        • 14.3.7.2. United Kingdom
        • 14.3.7.3. France
        • 14.3.7.4. Italy
        • 14.3.7.5. Spain
        • 14.3.7.6. Netherlands
        • 14.3.7.7. Nordic Countries
        • 14.3.7.8. Poland
        • 14.3.7.9. Russia & CIS
        • 14.3.7.10. Rest of Europe
    • 14.4. Germany AI in Pharmacovigilance Market
      • 14.4.1. Country Segmental Analysis
      • 14.4.2. Component
      • 14.4.3. Technology
      • 14.4.4. Deployment Mode
      • 14.4.5. Process Stage
      • 14.4.6. Application
      • 14.4.7. End-users
    • 14.5. United Kingdom AI in Pharmacovigilance Market
      • 14.5.1. Country Segmental Analysis
      • 14.5.2. Component
      • 14.5.3. Technology
      • 14.5.4. Deployment Mode
      • 14.5.5. Process Stage
      • 14.5.6. Application
      • 14.5.7. End-users
    • 14.6. France AI in Pharmacovigilance Market
      • 14.6.1. Country Segmental Analysis
      • 14.6.2. Component
      • 14.6.3. Technology
      • 14.6.4. Deployment Mode
      • 14.6.5. Process Stage
      • 14.6.6. Application
      • 14.6.7. End-users
    • 14.7. Italy AI in Pharmacovigilance Market
      • 14.7.1. Country Segmental Analysis
      • 14.7.2. Component
      • 14.7.3. Technology
      • 14.7.4. Deployment Mode
      • 14.7.5. Process Stage
      • 14.7.6. Application
      • 14.7.7. End-users
    • 14.8. Spain AI in Pharmacovigilance Market
      • 14.8.1. Country Segmental Analysis
      • 14.8.2. Component
      • 14.8.3. Technology
      • 14.8.4. Deployment Mode
      • 14.8.5. Process Stage
      • 14.8.6. Application
      • 14.8.7. End-users
    • 14.9. Netherlands AI in Pharmacovigilance Market
      • 14.9.1. Country Segmental Analysis
      • 14.9.2. Component
      • 14.9.3. Technology
      • 14.9.4. Deployment Mode
      • 14.9.5. Process Stage
      • 14.9.6. Application
      • 14.9.7. End-users
    • 14.10. Nordic Countries AI in Pharmacovigilance Market
      • 14.10.1. Country Segmental Analysis
      • 14.10.2. Component
      • 14.10.3. Technology
      • 14.10.4. Deployment Mode
      • 14.10.5. Process Stage
      • 14.10.6. Application
      • 14.10.7. End-users
    • 14.11. Poland AI in Pharmacovigilance Market
      • 14.11.1. Country Segmental Analysis
      • 14.11.2. Component
      • 14.11.3. Technology
      • 14.11.4. Deployment Mode
      • 14.11.5. Process Stage
      • 14.11.6. Application
      • 14.11.7. End-users
    • 14.12. Russia & CIS AI in Pharmacovigilance Market
      • 14.12.1. Country Segmental Analysis
      • 14.12.2. Component
      • 14.12.3. Technology
      • 14.12.4. Deployment Mode
      • 14.12.5. Process Stage
      • 14.12.6. Application
      • 14.12.7. End-users
    • 14.13. Rest of Europe AI in Pharmacovigilance Market
      • 14.13.1. Country Segmental Analysis
      • 14.13.2. Component
      • 14.13.3. Technology
      • 14.13.4. Deployment Mode
      • 14.13.5. Process Stage
      • 14.13.6. Application
      • 14.13.7. End-users
  • 15. Asia Pacific AI in Pharmacovigilance Market Analysis
    • 15.1. Key Segment Analysis
    • 15.2. Regional Snapshot
    • 15.3. Asia Pacific AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 15.3.1. Component
      • 15.3.2. Technology
      • 15.3.3. Deployment Mode
      • 15.3.4. Process Stage
      • 15.3.5. Application
      • 15.3.6. End-users
      • 15.3.7. Country
        • 15.3.7.1. China
        • 15.3.7.2. India
        • 15.3.7.3. Japan
        • 15.3.7.4. South Korea
        • 15.3.7.5. Australia and New Zealand
        • 15.3.7.6. Indonesia
        • 15.3.7.7. Malaysia
        • 15.3.7.8. Thailand
        • 15.3.7.9. Vietnam
        • 15.3.7.10. Rest of Asia Pacific
    • 15.4. China AI in Pharmacovigilance Market
      • 15.4.1. Country Segmental Analysis
      • 15.4.2. Component
      • 15.4.3. Technology
      • 15.4.4. Deployment Mode
      • 15.4.5. Process Stage
      • 15.4.6. Application
      • 15.4.7. End-users
    • 15.5. India AI in Pharmacovigilance Market
      • 15.5.1. Country Segmental Analysis
      • 15.5.2. Component
      • 15.5.3. Technology
      • 15.5.4. Deployment Mode
      • 15.5.5. Process Stage
      • 15.5.6. Application
      • 15.5.7. End-users
    • 15.6. Japan AI in Pharmacovigilance Market
      • 15.6.1. Country Segmental Analysis
      • 15.6.2. Component
      • 15.6.3. Technology
      • 15.6.4. Deployment Mode
      • 15.6.5. Process Stage
      • 15.6.6. Application
      • 15.6.7. End-users
    • 15.7. South Korea AI in Pharmacovigilance Market
      • 15.7.1. Country Segmental Analysis
      • 15.7.2. Component
      • 15.7.3. Technology
      • 15.7.4. Deployment Mode
      • 15.7.5. Process Stage
      • 15.7.6. Application
      • 15.7.7. End-users
    • 15.8. Australia and New Zealand AI in Pharmacovigilance Market
      • 15.8.1. Country Segmental Analysis
      • 15.8.2. Component
      • 15.8.3. Technology
      • 15.8.4. Deployment Mode
      • 15.8.5. Process Stage
      • 15.8.6. Application
      • 15.8.7. End-users
    • 15.9. Indonesia AI in Pharmacovigilance Market
      • 15.9.1. Country Segmental Analysis
      • 15.9.2. Component
      • 15.9.3. Technology
      • 15.9.4. Deployment Mode
      • 15.9.5. Process Stage
      • 15.9.6. Application
      • 15.9.7. End-users
    • 15.10. Malaysia AI in Pharmacovigilance Market
      • 15.10.1. Country Segmental Analysis
      • 15.10.2. Component
      • 15.10.3. Technology
      • 15.10.4. Deployment Mode
      • 15.10.5. Process Stage
      • 15.10.6. Application
      • 15.10.7. End-users
    • 15.11. Thailand AI in Pharmacovigilance Market
      • 15.11.1. Country Segmental Analysis
      • 15.11.2. Component
      • 15.11.3. Technology
      • 15.11.4. Deployment Mode
      • 15.11.5. Process Stage
      • 15.11.6. Application
      • 15.11.7. End-users
    • 15.12. Vietnam AI in Pharmacovigilance Market
      • 15.12.1. Country Segmental Analysis
      • 15.12.2. Component
      • 15.12.3. Technology
      • 15.12.4. Deployment Mode
      • 15.12.5. Process Stage
      • 15.12.6. Application
      • 15.12.7. End-users
    • 15.13. Rest of Asia Pacific AI in Pharmacovigilance Market
      • 15.13.1. Country Segmental Analysis
      • 15.13.2. Component
      • 15.13.3. Technology
      • 15.13.4. Deployment Mode
      • 15.13.5. Process Stage
      • 15.13.6. Application
      • 15.13.7. End-users
  • 16. Middle East AI in Pharmacovigilance Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. Middle East AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Component
      • 16.3.2. Technology
      • 16.3.3. Deployment Mode
      • 16.3.4. Process Stage
      • 16.3.5. Application
      • 16.3.6. End-users
      • 16.3.7. Country
        • 16.3.7.1. Turkey
        • 16.3.7.2. UAE
        • 16.3.7.3. Saudi Arabia
        • 16.3.7.4. Israel
        • 16.3.7.5. Rest of Middle East
    • 16.4. Turkey AI in Pharmacovigilance Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Component
      • 16.4.3. Technology
      • 16.4.4. Deployment Mode
      • 16.4.5. Process Stage
      • 16.4.6. Application
      • 16.4.7. End-users
    • 16.5. UAE AI in Pharmacovigilance Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Component
      • 16.5.3. Technology
      • 16.5.4. Deployment Mode
      • 16.5.5. Process Stage
      • 16.5.6. Application
      • 16.5.7. End-users
    • 16.6. Saudi Arabia AI in Pharmacovigilance Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Component
      • 16.6.3. Technology
      • 16.6.4. Deployment Mode
      • 16.6.5. Process Stage
      • 16.6.6. Application
      • 16.6.7. End-users
    • 16.7. Israel AI in Pharmacovigilance Market
      • 16.7.1. Country Segmental Analysis
      • 16.7.2. Component
      • 16.7.3. Technology
      • 16.7.4. Deployment Mode
      • 16.7.5. Process Stage
      • 16.7.6. Application
      • 16.7.7. End-users
    • 16.8. Rest of Middle East AI in Pharmacovigilance Market
      • 16.8.1. Country Segmental Analysis
      • 16.8.2. Component
      • 16.8.3. Technology
      • 16.8.4. Deployment Mode
      • 16.8.5. Process Stage
      • 16.8.6. Application
      • 16.8.7. End-users
  • 17. Africa AI in Pharmacovigilance Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Africa AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Component
      • 17.3.2. Technology
      • 17.3.3. Deployment Mode
      • 17.3.4. Process Stage
      • 17.3.5. Application
      • 17.3.6. End-users
      • 17.3.7. Country
        • 17.3.7.1. South Africa
        • 17.3.7.2. Egypt
        • 17.3.7.3. Nigeria
        • 17.3.7.4. Algeria
        • 17.3.7.5. Rest of Africa
    • 17.4. South Africa AI in Pharmacovigilance Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Component
      • 17.4.3. Technology
      • 17.4.4. Deployment Mode
      • 17.4.5. Process Stage
      • 17.4.6. Application
      • 17.4.7. End-users
    • 17.5. Egypt AI in Pharmacovigilance Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Component
      • 17.5.3. Technology
      • 17.5.4. Deployment Mode
      • 17.5.5. Process Stage
      • 17.5.6. Application
      • 17.5.7. End-users
    • 17.6. Nigeria AI in Pharmacovigilance Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Component
      • 17.6.3. Technology
      • 17.6.4. Deployment Mode
      • 17.6.5. Process Stage
      • 17.6.6. Application
      • 17.6.7. End-users
    • 17.7. Algeria AI in Pharmacovigilance Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Component
      • 17.7.3. Technology
      • 17.7.4. Deployment Mode
      • 17.7.5. Process Stage
      • 17.7.6. Application
      • 17.7.7. End-users
    • 17.8. Rest of Africa AI in Pharmacovigilance Market
      • 17.8.1. Country Segmental Analysis
      • 17.8.2. Component
      • 17.8.3. Technology
      • 17.8.4. Deployment Mode
      • 17.8.5. Process Stage
      • 17.8.6. Application
      • 17.8.7. End-users
  • 18. South America AI in Pharmacovigilance Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. South America AI in Pharmacovigilance Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Component
      • 18.3.2. Technology
      • 18.3.3. Deployment Mode
      • 18.3.4. Process Stage
      • 18.3.5. Application
      • 18.3.6. End-users
      • 18.3.7. Country
        • 18.3.7.1. Brazil
        • 18.3.7.2. Argentina
        • 18.3.7.3. Rest of South America
    • 18.4. Brazil AI in Pharmacovigilance Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Component
      • 18.4.3. Technology
      • 18.4.4. Deployment Mode
      • 18.4.5. Process Stage
      • 18.4.6. Application
      • 18.4.7. End-users
    • 18.5. Argentina AI in Pharmacovigilance Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Component
      • 18.5.3. Technology
      • 18.5.4. Deployment Mode
      • 18.5.5. Process Stage
      • 18.5.6. Application
      • 18.5.7. End-users
    • 18.6. Rest of South America AI in Pharmacovigilance Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Component
      • 18.6.3. Technology
      • 18.6.4. Deployment Mode
      • 18.6.5. Process Stage
      • 18.6.6. Application
      • 18.6.7. End-users
  • 19. Key Players/ Company Profile
    • 19.1. Cognizant Technology Solutions
      • 19.1.1. Company Details/ Overview
      • 19.1.2. Company Financials
      • 19.1.3. Key Customers and Competitors
      • 19.1.4. Business/ Industry Portfolio
      • 19.1.5. Product Portfolio/ Specification Details
      • 19.1.6. Pricing Data
      • 19.1.7. Strategic Overview
      • 19.1.8. Recent Developments
    • 19.2. Accenture
    • 19.3. ArisGlobal
    • 19.4. Capgemini SE
    • 19.5. ICON plc
    • 19.6. IQVIA
    • 19.7. Oracle Corporation
    • 19.8. Parexel International Corporation
    • 19.9. Tata Consultancy Services (TCS)
    • 19.10. Wipro Limited
    • 19.11. Other Key Players

 

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation